DAFNA Capital Management LLC Buys IDEAYA Biosciences Inc, Arcturus Therapeutics Holdings Inc, Translate Bio Inc, Sells Arena Pharmaceuticals Inc, Akebia Therapeutics Inc, Kura Oncology Inc

• New Purchases: IDYA, TBIO, SPPI, ALPN, SPRO, VRNA, DMAC, CHMA, CRDF,
• Added Positions: ARCT, ETNB, ASND, MEIP, NBIX, ARAY, OTIC, IMMU, NXTC, BPMC, MREO, AFMD, CNST, LQDA, STRO, IBB, AERI, KDMN,
• Reduced Positions: ARNA, AKBA, KURA, SNDX, CGEN, MRSN, SIOX, CARA, FATE, HOOK, LRMR, AGTC, ZYME, SAGE, ARDX, BHVN, KALV, ISEE, APLS, SCPH,
• Sold Out: MRTX, TPTX, ZGNX, GNCA, AUTL, CRBP, MORF, CERC, SYBX, SLNO, TCRR, LPTX, CBAY, ALRN, PRVB, GRTS, RIGL, CTMX,

For the details of DAFNA Capital Management LLC's stock buys and sells, go to https://www.gurufocus.com/guru/dafna+capital+management+llc/current-portfolio/portfolio

1. Stereotaxis Inc (STXS) - 13,680,554 shares, 16.20% of the total portfolio.
2. Immunomedics Inc (IMMU) - 260,905 shares, 7.34% of the total portfolio. Shares added by 3.99%
3. Blueprint Medicines Corp (BPMC) - 233,089 shares, 7.15% of the total portfolio. Shares added by 2.19%
4. Fate Therapeutics Inc (FATE) - 438,460 shares, 5.80% of the total portfolio. Shares reduced by 10.68%
5. Arcturus Therapeutics Holdings Inc (ARCT) - 229,652 shares, 3.26% of the total portfolio. Shares added by 54.11%

DAFNA Capital Management LLC initiated holding in IDEAYA Biosciences Inc. The purchase prices were between $11.22 and $14.46, with an estimated average price of $12.39. The stock is now traded at around $13.19. The impact to a portfolio due to this purchase was 1.38%. The holding were 331,661 shares as of .

DAFNA Capital Management LLC initiated holding in Translate Bio Inc. The purchase prices were between $12.43 and $19.73, with an estimated average price of $15.41. The stock is now traded at around $17.61. The impact to a portfolio due to this purchase was 0.86%. The holding were 190,930 shares as of .

DAFNA Capital Management LLC initiated holding in Spectrum Pharmaceuticals Inc. The purchase prices were between $2.99 and $4.9, with an estimated average price of $3.8. The stock is now traded at around $4.09. The impact to a portfolio due to this purchase was 0.69%. The holding were 514,891 shares as of .

DAFNA Capital Management LLC initiated holding in Alpine Immune Sciences Inc. The purchase prices were between $7.15 and $11.5, with an estimated average price of $9.13. The stock is now traded at around $7.96. The impact to a portfolio due to this purchase was 0.43%. The holding were 148,260 shares as of .

DAFNA Capital Management LLC initiated holding in Spero Therapeutics Inc. The purchase prices were between $8.96 and $14.12, with an estimated average price of $11.81. The stock is now traded at around $14.85. The impact to a portfolio due to this purchase was 0.37%. The holding were 100,000 shares as of .

DAFNA Capital Management LLC initiated holding in Verona Pharma PLC. The purchase prices were between $4.45 and $10.2, with an estimated average price of $6.87. The stock is now traded at around $7.55. The impact to a portfolio due to this purchase was 0.33%. The holding were 161,507 shares as of .

DAFNA Capital Management LLC added to a holding in Arcturus Therapeutics Holdings Inc by 54.11%. The purchase prices were between $37.49 and $63.19, with an estimated average price of $49.42. The stock is now traded at around $56.34. The impact to a portfolio due to this purchase was 1.14%. The holding were 229,652 shares as of .

DAFNA Capital Management LLC added to a holding in 89bio Inc by 439.50%. The purchase prices were between $24.34 and $38.82, with an estimated average price of $31.73. The stock is now traded at around $26.15. The impact to a portfolio due to this purchase was 0.77%. The holding were 110,478 shares as of .

DAFNA Capital Management LLC added to a holding in Ascendis Pharma A/S by 105.36%. The purchase prices were between $134.29 and $154.32, with an estimated average price of $143.8. The stock is now traded at around $152.71. The impact to a portfolio due to this purchase was 0.76%. The holding were 29,237 shares as of .

DAFNA Capital Management LLC added to a holding in MEI Pharma Inc by 1110.91%. The purchase prices were between $2.46 and $4.27, with an estimated average price of $3.01. The stock is now traded at around $2.78. The impact to a portfolio due to this purchase was 0.63%. The holding were 666,000 shares as of .

DAFNA Capital Management LLC added to a holding in Neurocrine Biosciences Inc by 23.22%. The purchase prices were between $96.16 and $135.15, with an estimated average price of $115.74. The stock is now traded at around $86.91. The impact to a portfolio due to this purchase was 0.54%. The holding were 90,208 shares as of .

DAFNA Capital Management LLC added to a holding in Accuray Inc by 59.32%. The purchase prices were between $1.98 and $2.74, with an estimated average price of $2.33. The stock is now traded at around $3.94. The impact to a portfolio due to this purchase was 0.32%. The holding were 1,074,300 shares as of .

DAFNA Capital Management LLC sold out a holding in Mirati Therapeutics Inc. The sale prices were between $113.26 and $167.27, with an estimated average price of $136.56.

DAFNA Capital Management LLC sold out a holding in Turning Point Therapeutics Inc. The sale prices were between $56.99 and $89.33, with an estimated average price of $69.62.

DAFNA Capital Management LLC sold out a holding in Zogenix Inc. The sale prices were between $17.5 and $29.36, with an estimated average price of $24.56.

DAFNA Capital Management LLC sold out a holding in Genocea Biosciences Inc. The sale prices were between $1.81 and $5.53, with an estimated average price of $2.61.

DAFNA Capital Management LLC sold out a holding in Autolus Therapeutics PLC. The sale prices were between $11.64 and $16.3, with an estimated average price of $14.47.

DAFNA Capital Management LLC sold out a holding in Corbus Pharmaceuticals Holdings Inc. The sale prices were between $1.51 and $9.38, with an estimated average price of $6.11.